Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

intervet international bv (boxmer), holland (0000005707) wim de körverstraat 35,5831 an boxmeer,boxmeer,nl - inactivated bordetella bronchiseptica cells; protein do (non-toxic deletion derivative of pasteurella multocida dermonecrotic toxin) - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - inactivated bordetella bronchiseptica cells 0,00 inj.susp 0; protein do (non-toxic deletion derivative of pasteurella multocida dermonecrotic toxin) 0,00 inj.susp 0 - bordetella + pasteurella - Χοίροι - Χρόνοι αναμονής: Χοίροι 0 Ημέρες Κρέας και εδώδιμοι ιστοί

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

intervet international bv (boxmer), holland (0000005707) wim de körverstraat 35,5831 an boxmeer,boxmeer,nl - inactivated whole cel suspension of ornithobacterium rhinotracheale serotype a, strain b3263/91 - ΕΝΕΣΙΜΟ ΓΑΛΑΚΤΩΜΑ - 1 x 10^7 cells/dose - inactivated whole cel suspension of ornithobacterium rhinotracheale serotype a, strain b3263/91 0,00 em.inj 1 x 10^7 cells/dose - ornithobacterium - Όρνιθες - Χρόνοι αναμονής: Όρνιθες 0 Ημέρες Κρέας και εδώδιμοι ιστοί

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - Αιμορραγικό Πυρετό, Του Έμπολα - Εμβόλια - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

laboratorios hipra s.a. spain (0000003524) avinguda la selva, 135,17170,amer (girona),es - lipoteichoic acid (lta) from biofilm adhesion component (bac) of streptococcus uberis strain 5616 - ΕΝΕΣΙΜΟ ΓΑΛΑΚΤΩΜΑ - lipoteichoic acid (lta) from biofilm adhesion component (bac) of streptococcus uberis strain 5616 0,00 em.inj 0 - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - Βοοειδή - Χρόνοι αναμονής: Βοοειδή 0 Ημέρες Κρέας και εδώδιμοι ιστοί

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

laboratorios hipra s.a. spain (0000003524) avinguda la selva, 135,17170,amer (girona),es - aluminium hydroxide gel; ginseng; e. coli strain p4 (f6 adhesins); e. coli strain p6 (f4ac adhesins); e. coli ΠΑΡΑΓΟΝΤΑΣ ΠΡΟΣΚΟΛΛΗΣΗΣ Κ88 ab; c. novyi toxoid; b toixoid of c. perfringens type c; escherichia coli (lt) enterotoxin; escherichia coli inactivia f5 (o 101:k99) - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - aluminium hydroxide gel 0,50 inj.susp 0; ginseng 4,00 inj.susp 0; e. coli strain p4 (f6 adhesins) 80,00 inj.susp 0; e. coli strain p6 (f4ac adhesins) 78,00 inj.susp 0; e. coli ΠΑΡΑΓΟΝΤΑΣ ΠΡΟΣΚΟΛΛΗΣΗΣ Κ88 ab 65,00 inj.susp 0; c. novyi toxoid 50,00 inj.susp 0; b toixoid of c. perfringens type c 35,00 inj.susp 0; escherichia coli (lt) enterotoxin 55,00 inj.susp 0; escherichia coli inactivia f5 (o 101:k99) 79,00 inj.susp 0 - escherichia + clostridium - Χοίροι - Χρόνοι αναμονής: Χοίροι 0 Ημέρες Κρέας και εδώδιμοι ιστοί

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

virbac s.a., carros, france (0000006112) 1 avenue 2065,,m-lid 06516 carros,fr - recombinant omega interferon of feline origin - ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 5mu/ml - recombinant omega interferon of feline origin 5,00 ly.insp.sv 5mu/ml - interferons - Γάτες; Σκύλοι - Χρόνοι αναμονής: Σκύλοι; Γάτες

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

lab. hipra s.a., amer-girona, spain (0000007652) avda la selva, 135,e-17170,amer,es - recombinant verotoxin 2e of e.coli - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - recombinant verotoxin 2e of e.coli 0,00 inj.susp 0 - escherichia - Χοίροι - Χρόνοι αναμονής: Χοίροι 0 Ημέρες Κρέας και εδώδιμοι ιστοί

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

virbac s.a., carros, france (0000006112) 1 avenue 2065,,m-lid 06516 carros,fr - recombinant omega interferon of feline origin - ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 10mu/ml - recombinant omega interferon of feline origin 10,00 ly.insp.sv 10mu/ml - interferons - Γάτες; Σκύλοι - Χρόνοι αναμονής: Σκύλοι; Γάτες

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - Κοτόπουλο - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - Εμβόλια - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. Η χρήση αυτού του εμβολίου θα πρέπει να γίνεται σύμφωνα με τις επίσημες συστάσεις.